NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Met Non Small Cell Cancer Registry (MOMENT)

RecruitingN/A

Sponsor: EMD Serono Research & Development Institute, Inc.

Conditions: Cancer

Countries: United States, Austria, Belgium, Canada, Czechia, France, Germany, Israel

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Participants who signed ICF
* Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
* Participants who are starting or are already being treated with systemic therapy

Exclusion Criteria:

* Participants who are enrolled in a clinical trial

Locations (79)

Fort Lauderdale, Florida, United States
Columbus, Ohio, United States
Nashville, Tennessee, United States
Klagenfurt, Austria
Salzburg, Austria
Vienna, Austria
Hasselt, Belgium
Roeselare, Belgium
Sint-Niklaas, Belgium
Yvoir, Belgium
Ottawa, Canada
Québec, Canada
Toronto, Canada
Vancouver, Canada
Olomouc, Czechia
Prague, Czechia
Cholet, France
Lille, France
Lorient, France
Lyon, France
Paris, France
Paris, France
Paris, France
Rennes, France
Toulouse, France
Chemnitz, Germany
Großhansdorf, Germany
Heidelberg, Germany
Löwenstein, Germany
Afula, Israel
+ 49 more on CT.gov